Clinical Trial Detail

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT06320067
Title	A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer (STAMPEDE2)
Acronym	STAMPEDE2
Recruitment	Recruiting
Gender	male
Phase	Phase III
Variant Requirements	No
Sponsors	University College, London
Indications	prostate adenocarcinoma
Therapies	Darolutamide + lutetium Lu 177 vipivotide tetraxetan Abiraterone + lutetium Lu 177 vipivotide tetraxetan + Prednisolone Apalutamide + lutetium Lu 177 vipivotide tetraxetan Abiraterone + Docetaxel + lutetium Lu 177 vipivotide tetraxetan + Prednisolone Darolutamide Abiraterone + Docetaxel + Prednisone Enzalutamide + lutetium Lu 177 vipivotide tetraxetan Docetaxel + Niraparib and abiraterone acetate + Prednisolone Niraparib and abiraterone acetate + Prednisone Docetaxel + Enzalutamide + lutetium Lu 177 vipivotide tetraxetan Darolutamide + Docetaxel + lutetium Lu 177 vipivotide tetraxetan Apalutamide + Docetaxel + lutetium Lu 177 vipivotide tetraxetan Enzalutamide Apalutamide + Docetaxel Docetaxel + Enzalutamide Apalutamide Abiraterone + Prednisone Darolutamide + Docetaxel
Age Groups:	adult \| senior
Covered Countries	GBR

Facility	Status	City	Zip	Country	Details
Royal Devon University Hospital Trust	RECRUITING	Exeter	EX2 5DW	United Kingdom	Details
University College London Hospitals NHS Foundation Trust	RECRUITING	London	NW3 2PG	United Kingdom	Details
The Royal Marsden Hospital	RECRUITING	London	SW3 6JJ	United Kingdom	Details
The Royal Marsden Hospital	RECRUITING	Sutton	SM2 5PT	United Kingdom	Details

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field